Alnylam Pharmaceuticals ALNY is a commercial-stage company that currently markets four drugs. The company first received regulatory approval in 2018 for Onpattro to treat adult patients with ...

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731812786/en/ The articles, information, and content displayed on this webpage ...

What if mRNA vaccines could be made more powerful and less irritating? Scientists at the University of Pennsylvania have found a way to do just that—by tweaking a key molecule in the vaccine’s ...

New research from scientists at the University of Pennsylvania shows that by tweaking the structure of the ionizable lipid component of lipid nanoparticles (LNPs), they can reduce side effects such as ...

As millions of people know firsthand, the most common side effect of mRNA vaccines like the COVID-19 shot is inflammation: soreness, redness and a day or two of malaise. But what if mRNA vaccines ...

As millions of people know firsthand, the most common side effect of mRNA vaccines like the COVID-19 shot is inflammation: soreness, redness and a day or two of malaise. But what if mRNA vaccines ...

Jordan Kilganon shows off amazing dunks at Cambrian College. Watch his impressive basketball skills! President Trump addresses the nation after US attacks three nuclear sites in Iran Amy Poehler Says ...

Alnylam Pharmaceuticals has won expanded European Commission approval of its Amvuttra drug for use in a rare and potentially fatal heart condition. The Cambridge, Mass., biopharmaceutical company on ...

Amyloidosis is a condition where a protein called amyloid builds up in your organs and tissues. It can be hereditary, meaning it is passed down in families due to broken genes, or it can happen ...

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the ...

For rare disease marketers, choosing the right patient to partner with for a campaign can often feel like finding a needle in a haystack. According to Mara Molinello, head of rare disease at Alnylam ...